ArticleEBioMedicine2019
Adult immune compromised zebrafish for xenograft cell transplantation studies.
Abstract read
In one paragraph
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Beyond the mouse: 3R-guided alternative animal models transforming cancer research.Molecular cancer · 2026Review
- Zebrafish as a multimodal platforms for anti-inflammatory phytomedicine discovery and translation.Frontiers in pharmacology · 2026Review
- IL-26 from innate lymphoid cells regulates early-life gut epithelial homeostasis by shaping microbiota composition.The EMBO journal · 2025Article
- Zebrafish Models of Induced Lymphangiogenesis: Current Advancements and Therapeutic Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Robust statistical assessment of Oncogenotype to Organotropism translation in xenografted zebrafish.bioRxiv : the preprint server for biology · 2025Article
- Zebrafish identification with deep CNN and ViT architectures using a rolling training window.Scientific reports · 2025Article
- The paradigm shift: re-evaluating preclinical animal models for colorectal cancer in the precision medicine era.Frontiers in immunology · 2025Review
- Zebrafish-A Suitable Model for Rapid Translation of Effective Therapies for Pediatric Cancers.Cancers · 2024Review
- Longitudinal investigation of a xenograft tumor zebrafish model using polarization-sensitive optical coherence tomography.Scientific reports · 2022Article
- Zebrafish Models of Paediatric Brain Tumours.International journal of molecular sciences · 2022Review
- Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials.Nature reviews. Drug discovery · 2021Review
- Zebrafish Models for the Safety and Therapeutic Testing of Nanoparticles with a Focus on Macrophages.Nanomaterials (Basel, Switzerland) · 2021Review
- Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.Neuro-oncology · 2021Review
- Review
- Cellular and Molecular Mechanisms Underlying Glioblastoma and Zebrafish Models for the Discovery of New Treatments.Cancers · 2021Review
- The Use of Zebrafish Xenotransplant Assays to Analyze the Role of lncRNAs in Breast Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Chuan YanMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America; Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America; Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America.
Qiqi YangMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America; Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America; Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America.
Daniel DoMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America; Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America; Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America.
Dalton C BrunsonMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America; Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America; Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America.
David M LangenauMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America; Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America; Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America. Electronic address: dlangenau@mgh.harvard.edu.
Funding
Immune Compromises Zebrafish for Cell TransplantationR24OD016761 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2013 to 2021
$5.2MGenetics of RhabdomyosarcomaR01CA154923 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2011 to 2021
$3.8MOncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemiaR01CA211734 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2017 to 2021
$1.9MStem cell self-renewal programs in rhabdomyosarcomaR01CA215118 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2018 to 2022
$1.9MNCI NIH HHS R01 CA154923NCI NIH HHS R01 CA211734NCI NIH HHS R01 CA215118NIH HHS R24 OD016761
Abstract
PubMed holds no abstract for this paper.
Indexed as
Disease Models, AnimalZebrafishAnimalsHumansImmunocompromised HostNeoplasmsNeoplasm TransplantationTransplantation, HeterologousXenograft Model Antitumor Assays
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.